MedTrace Logo

A Long-Term Follow-Up Study of Participants Exposed to REACT

NCT05918523 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2025-05-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the long-term safety of up to two gelatin-hydrogel formulation REACT injections given 3 to 6 months apart and delivered percutaneously into same kidney on renal function in participants with chronic kidney disease (CKD).

Conditions

  • Diabetic Kidney Disease
  • Chronic Kidney Diseases

Interventions

BIOLOGICAL

Renal Autologous Cell Therapy (REACT)

No interventions in this trial

Sponsors & Collaborators

  • Prokidney

    lead INDUSTRY

Principal Investigators

  • Study Director · Prokidney

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-11
Primary Completion
2028-01-31
Completion
2028-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05918523 on ClinicalTrials.gov